KDs increased tumor-reactive immune responses, including tumor infiltration of cytotoxic CD8+ T cells in malignant glioma mouse model and reduced the expression of T cell co-inhibitory receptors CTLA-4 and PD-1 and their ligands CD86 and PD-L1 [193]. The gene discussed is CD86; the disease is neoplasm.